Skip to main content
Clinical Trials/NL-OMON47361
NL-OMON47361
Completed
N/A

Clinical performance of a new implant system for bone conduction hearing - CBAS5539

Cochlear Bone Anchored Solutions AB0 sites10 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
deafness
Sponsor
Cochlear Bone Anchored Solutions AB
Enrollment
10
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • \* Adult subjects (18 years or older)
  • \* Subject with conductive or mixed hearing loss in the ear to be implanted. Bone conduction thresholds with pure tone average (PTA4; mean of 0\.5, 1, 2 and 4 kHz) of \<\<\= 55 dB.
  • Subject with single\-sided sensorineural deafness who is a candidate for Baha surgery. Air conduction thresholds with a pure tone average PTA4 of \<\<\= 20 dB HL (mean of 0\.5, 1, 2 and 3 kHz) in the good ear
  • Subject who is indicated for an AC CROS but\*for some reason\*cannot or will not use an AC CROS (Air Conduction\-Contralateral Routing of Signal).
  • \* Signed informed consent
  • \* Previous experience from amplified sound though properly fitted amplication. (For example but not limited to Hearing aid, CROS device, Bone conductional hearing device on headband/ softband)

Exclusion Criteria

  • \* Uncontrolled diabetes as judged by the investigator.
  • \* Condition that could jeopardise osseointegration and/or wound healing (e.g. osteoporosis, psoriasis, long\-term systemic use of corticosteroids) or condition that may have an impact on the outcome of the investigation as judged by the investigator.
  • \* Insufficient bone quality and quantity for implantation of a BI300 Implant.
  • \* Subject that has received radiotherapy in the area of implantation, or is planned for such radiotherapy during the study period.
  • \* Use of ototoxic drugs that could be harmful to the hearing, as judged by the investigator.
  • \* Unable to follow investigational procedures, e.g. to complete quality of life scales.
  • \* Participation in another clinical investigation with pharmaceutical and/or device.
  • \* The subject is pregnant or lactating
  • \* The subject suffers from psychiatric and/or psychomatic disorder(s)

Outcomes

Primary Outcomes

Not specified

Similar Trials